Graphene derivatives potentiate the activity of antibiotics against Enterococcus faecium, Klebsiella pneumoniae and Escherichia coli

Jonathan A. Butler; Lauren Osborne; Mohamed El Mohtadi; Kathryn A. Whitehead; Jonathan A. Butler; Lauren Osborne; Mohamed El Mohtadi; Kathryn A. Whitehead

doi:10.3934/bioeng.2020010

AIMS Bioengineering

2020, Volume 7, Issue 2: 106-113. doi: 10.3934/bioeng.2020010

Previous Article Next Article

Communication Special Issues

Graphene derivatives potentiate the activity of antibiotics against Enterococcus faecium, Klebsiella pneumoniae and Escherichia coli

Microbiology at Interfaces, Manchester Metropolitan University, Chester Street, Manchester M1 5GD, UK

Received: 24 April 2020 Accepted: 26 May 2020 Published: 03 June 2020

Antibiotic resistance in bacteria is developing at a faster rate than new antibiotics can be discovered. This study investigated the antimicrobial activity of several carbon-based derivative compounds alone and in combination with clinically relevant antibiotics against key ESKAPE pathogens Enterococcus faecium, Klebsiella pneumoniae and Escherichia coli. Three compounds, graphite, graphene and graphene oxide, in conjunction with ciprofloxacin (CIP), chloramphenicol (CHL) and piperacillin/tazobactam (TZP) were examined using fractional inhibitory concentration (FIC) testing. CIP combined with graphene demonstrated additive antimicrobial activity against E. faecium compared to individual application. Furthermore, CIP supplemented with graphene, graphene oxide or graphite showed additive activity with ∑FIC values of 1.0 against K. pneumoniae, whereas only TZP showed ∑FIC values <1.0 with graphene oxide. For E. coli, the antibiotic activity of CIP was enhanced with graphene, graphene oxide or graphite, whereas only graphite and graphene enhanced the activity of CHL and TZP respectively. Graphite and graphene oxide caused significant antagonism (∑FIC > 4.0) in conjunction with TZP against E. coli. In conclusion, the results demonstrate the potential to supplement clinically relevant antibiotics with carbon-based graphene, graphene oxide derivative or graphite for use as an additive supplement for novel systemic or topical treatment solutions against key priority pathogens.
- graphene,
- ESKAPE pathogens,
- synergy,
- antibiotics,
- chloramphenicol,
- ciprofloxacin,
- piperacillin-tazobactam
Citation: Jonathan A. Butler, Lauren Osborne, Mohamed El Mohtadi, Kathryn A. Whitehead. Graphene derivatives potentiate the activity of antibiotics against Enterococcus faecium, Klebsiella pneumoniae and Escherichia coli[J]. AIMS Bioengineering, 2020, 7(2): 106-113. doi: 10.3934/bioeng.2020010

Related Papers:

Abstract

Antibiotic resistance in bacteria is developing at a faster rate than new antibiotics can be discovered. This study investigated the antimicrobial activity of several carbon-based derivative compounds alone and in combination with clinically relevant antibiotics against key ESKAPE pathogens Enterococcus faecium, Klebsiella pneumoniae and Escherichia coli. Three compounds, graphite, graphene and graphene oxide, in conjunction with ciprofloxacin (CIP), chloramphenicol (CHL) and piperacillin/tazobactam (TZP) were examined using fractional inhibitory concentration (FIC) testing. CIP combined with graphene demonstrated additive antimicrobial activity against E. faecium compared to individual application. Furthermore, CIP supplemented with graphene, graphene oxide or graphite showed additive activity with ∑FIC values of 1.0 against K. pneumoniae, whereas only TZP showed ∑FIC values <1.0 with graphene oxide. For E. coli, the antibiotic activity of CIP was enhanced with graphene, graphene oxide or graphite, whereas only graphite and graphene enhanced the activity of CHL and TZP respectively. Graphite and graphene oxide caused significant antagonism (∑FIC > 4.0) in conjunction with TZP against E. coli. In conclusion, the results demonstrate the potential to supplement clinically relevant antibiotics with carbon-based graphene, graphene oxide derivative or graphite for use as an additive supplement for novel systemic or topical treatment solutions against key priority pathogens.

Acknowledgments

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

All authors declare no conflicts of interest in this paper.

References

[1]	Blair JMA, Webber MA, Baylay AJ, et al. (2015) Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13: 42-51. doi: 10.1038/nrmicro3380
[2]	Perez KK, Olsen RJ, Musick WL, et al. (2014) Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia. J Infect 69: 216-225. doi: 10.1016/j.jinf.2014.05.005
[3]	Gao Y, Wu J, Ren X, et al. (2017) Impact of graphene oxide on the antibacterial activity of antibiotics against bacteria. Environ Sci Nano 4: 1016-1024. doi: 10.1039/C7EN00052A
[4]	Slate AJ, Karaky N, Whitehead KA (2018) Antimicrobial properties of modified graphene and other advanced 2D material coated surfaces. 2D Materials: Characterization, Production and Applications CRC Press, 86-104. doi: 10.1201/9781315152042-5
[5]	Raccichini R, Varzi A, Passerini S, et al. (2015) The role of graphene for electrochemical energy storage. Nat Mater 14: 271-279. doi: 10.1038/nmat4170
[6]	Mogharabi M, Abdollahi M, Faramarzi MA (2014) Safety concerns to application of graphene compounds in pharmacy and medicine. DARU J Pharm Sci 22: 23. doi: 10.1186/2008-2231-22-23
[7]	Ferrari AC (2007) Raman spectroscopy of graphene and graphite: disorder, electron–phonon coupling, doping and nonadiabatic effects. Solid State Commun 143: 47-57. doi: 10.1016/j.ssc.2007.03.052
[8]	Liu S, Zeng TH, Hofmann M, et al. (2011) Antibacterial activity of graphite, graphite oxide, graphene oxide, and reduced graphene oxide: membrane and oxidative stress. ACS Nano 5: 6971-6980. doi: 10.1021/nn202451x
[9]	Zou X, Zhang L, Wang Z, et al. (2016) Mechanisms of the antimicrobial activities of graphene materials. J Am Chem Soc 138: 2064-2077. doi: 10.1021/jacs.5b11411
[10]	Chen J, Wang X, Han H (2013) A new function of graphene oxide emerges: inactivating phytopathogenic bacterium Xanthomonas oryzae pv. Oryzae. J Nanopart Res 15: 1658. doi: 10.1007/s11051-013-1658-6
[11]	Kapoor G, Saigal S, Elongavan A (2017) Action and resistance mechanisms of antibiotics: a guide for clinicians. J Anaesthesiol Clin Pharmacol 33: 300-305. doi: 10.4103/joacp.JOACP_349_15
[12]	Karaky N, Kirby A, McBain AJ, et al. (2020) Metal ions and graphene-based compounds as alternative treatment options for burn wounds infected by antibiotic-resistant Pseudomonas aeruginosa.DOI: https://doi.org/10.1007/s00203-019-01803-z.
[13]	Vi TTT, Kumar SR, Pang J-HS, et al. (2020) Synergistic antibacterial activity of silver-loaded graphene oxide towards Staphylococcus aureus and Escherichia coli. Nanomaterials 10: 366. doi: 10.3390/nano10020366
[14]	Bugli F, Cacaci M, Palmieri V, et al. (2018) Curcumin-loaded graphene oxide flakes as an effective antibacterial system against methicillin-resistant Staphylococcus aureus. Interface focus 8: 20170059. doi: 10.1098/rsfs.2017.0059
[15]	Singh V, Kumar V, Kashyap S, et al. (2019) Graphene oxide synergistically enhances antibiotic efficacy in vancomycin-resistant Staphylococcus aureus. ACS Appl Bio Mater 2: 1148-1157. doi: 10.1021/acsabm.8b00757
[16]	Drlica K, Malik M, Kerns RJ, et al. (2008) Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52: 385-392. doi: 10.1128/AAC.01617-06
[17]	Xaplanteri MA, Andreou A, Dinos GP, et al. (2003) Effect of polyamines on the inhibition of peptidyltransferase by antibiotics: revisiting the mechanism of chloramphenicol action. Nucleic Acids Res 31: 5074-5083. doi: 10.1093/nar/gkg686
[18]	Walsh C (2000) Molecular mechanisms that confer antibacterial drug resistance. Nature 406: 775-781. doi: 10.1038/35021219
[19]	Soares GMS, Figueiredo LC, Faveri M, et al. (2012) Mechanisms of action of systemic antibiotics used in periodontal treatment and mechanisms of bacterial resistance to these drugs. J Appl Oral Sci 20: 295-309. doi: 10.1590/S1678-77572012000300002
[20]	Boucher HW, Talbot GH, Benjamin DK, et al. (2013) 10×'20 progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56: 1685-1694. doi: 10.1093/cid/cit152
[21]	Sopirala MM, Mangino JE, Gebreyes WA, et al. (2010) Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54: 4678-4683. doi: 10.1128/AAC.00497-10
[22]	Melander RJ, Melander C (2017) The challenge of overcoming antibiotic resistance: an adjuvant approach? ACS Infect Dis 3: 559-563. doi: 10.1021/acsinfecdis.7b00071
[23]	Yang Y, Rasmussen BA, Shlaes DM (1999) Class A β-lactamases—enzyme-inhibitor interactions and resistance. Pharmacol Ther 83: 141-151. doi: 10.1016/S0163-7258(99)00027-3
[24]	Zhou A, Kang TM, Yuan J, et al. (2015) Synergistic interactions of vancomycin with different antibiotics against Escherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli. Antimicrob Agents Chemother 59: 276-281. doi: 10.1128/AAC.03502-14

Reader Comments

your name:*

Email:*
© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)